AI Article Synopsis
- The study aimed to assess the safety of giving Tdap and influenza vaccines together during pregnancy by comparing adverse events between women who received both vaccines at the same time versus those who received them one after the other.
- Researchers analyzed data from 36,844 pregnancies and found that only a small fraction received both vaccines simultaneously (23%). They discovered no significant increase in fever or other acute medical events in women vaccinated together compared to those vaccinated sequentially.
- Results showed that there were no differences in adverse birth outcomes, like preterm delivery or low birth weight, between the two groups, concluding that giving both vaccines simultaneously is safe for pregnant women.
Article Abstract
Objective: To evaluate the safety of coadministering tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) and influenza vaccines during pregnancy by comparing adverse events after concomitant and sequential vaccination.
Methods: We conducted a retrospective cohort study of pregnant women aged 14-49 years in the Vaccine Safety Datalink from January 1, 2007, to November 15, 2013. We compared medically attended acute events (fever, any acute reaction) and adverse birth outcomes (preterm delivery, low birth weight, small for gestational age) in women receiving concomitant Tdap and influenza vaccination and women receiving sequential vaccination.
Results: Among 36,844 pregnancies in which Tdap and influenza vaccines were administered, the vaccines were administered concomitantly in 8,464 (23%) pregnancies and sequentially in 28,380 (77%) pregnancies. Acute adverse events after vaccination were rare. We found no statistically significant increased risk of fever or any medically attended acute adverse event in pregnant women vaccinated concomitantly compared with sequentially. When analyzing women at 20 weeks of gestation or greater during periods of influenza vaccine administration, there were no differences in preterm delivery, low-birth-weight, or small-for-gestational-age neonates between women vaccinated concomitantly compared with sequentially in pregnancy.
Conclusion: Concomitant administration of Tdap and influenza vaccines during pregnancy was not associated with a higher risk of medically attended adverse acute outcomes or birth outcomes compared with sequential vaccination.
Level Of Evidence: II.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618722 | PMC |
| http://dx.doi.org/10.1097/AOG.0000000000001066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Post-Vaccination Anaphylaxis in Adults: A Systematic Review and Meta-Analysis.
Vaccines (Basel)
January 2025
School of Medicine, Università Vita-Salute San Raffaele, 20132 Milan, Italy.
Background/objectives: Vaccines have been recognized as one of the most effective public health interventions. However, vaccine-associated anaphylaxis, although rare, is a serious adverse reaction. The incidence of anaphylaxis related to non-COVID-19 vaccines in adults remains underreported.
View Article and Find Full Text PDFImmunisation schedule of the Pediatric Spanish Association: 2024 recommendations.
An Pediatr (Engl Ed)
January 2025
Pediatrician, Barcelona, Spain.
The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties: Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age. As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age. Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10-12 years of age.
View Article and Find Full Text PDFVaccine Acceptance Among Pregnant Women in Israel During COVID-19: Influences and Decision-Making Factors.
Vaccines (Basel)
December 2024
The Shamir Medical Center (Assaf Harofeh), Rishon LeZion, 4 Icet, Zrifin 7033001, Israel.
In response to the COVID-19 pandemic, Israel prioritized pregnant women for vaccination, recognizing them as a high-risk group. This study aims to explore factors influencing the acceptance of Influenza, Pertussis (T-dap), and COVID-19 vaccines among pregnant women, focusing on attitudes, social norms, perceived control, and risk perceptions. Additionally, the study compares acceptance patterns between traditional vaccines and the newer COVID-19 vaccine.
View Article and Find Full Text PDFAtrial Fibrillation after RSV Vaccination Among Older Adults.
Clin Infect Dis
December 2024
Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.
RSV vaccine clinical trials reported higher frequencies of atrial fibrillation in intervention groups compared to control. In this large, population-based, propensity-matched study, we found RSV vaccine was not associated with increased risk of new-onset or recurrent atrial fibrillation within 1-42 days compared to influenza or Tdap vaccines.
View Article and Find Full Text PDFA Model for Consolidating High-Risk Allergy Procedures in Clinic.
Ochsner J
January 2024
Department of Allergy and Immunology, Ochsner Clinic Foundation, New Orleans, LA.
Allergists perform a range of procedures with inherent risks of anaphylaxis. This study developed risk assessments for various procedures performed at our specialized referral center based on the frequency of epinephrine use during these procedures. During a 5.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!